

Information about Epinephrine Shortage: Impact on Medicaid

Information posted August 16, 2019

In June, Mylan [issued an alert](#) on the manufacturing challenges involved in the production of EpiPen (epinephrine injection, USP) 0.3 mg, EpiPen Jr (epinephrine injection, USP) 0.15 mg Auto-Injectors, and the authorized generic versions of these products. These manufacturing challenges resulted in the reduced availability of these products. Effective July 26, 2019, the Vendor Drug Program (VDP) temporarily removed the non-preferred status from the following epinephrine National Drug Codes (NDCs) for people enrolled in Medicaid:

NDC	Name
00115169449	Epinephrine 0.3 mg Auto-Injector
00115169549	Epinephrine 0.15 mg Auto-Injector

This change allows providers to temporarily prescribe the two product NDCs listed above without submitting the Preferred Drug List (PDL) prior authorization that is usually required. This change allows continued access to necessary medication for Medicaid clients.

The following are the current preferred products:

NDC	Name
49502010101	Epinephrine 0.15 mg Auto-Injector
49502010102	Epinephrine 0.15 mg Auto-Injector
49502010201	Epinephrine 0.3 mg Auto-Injector
49502010202	Epinephrine 0.3 mg Auto-Injector

This change is temporary, until the preferred products are sufficiently available in the market. VDP will announce future PDL status changes for these NDCs.

Email vdp-formulary@hsc.state.tx.us for questions or more information.